Prediction of Clinically Significant Prostate Cancer in MR/Ultrasound Guided Fusion Biopsy using Multiparametric MRI

Wen Shi*  
jsnsw97@stu.xjtu.edu.cn  
Karthik V. Sarma†  
ksarma@mednet.ucla.edu  
Alex G. Raman†  
araman@mednet.ucla.edu  
Alan M. Priester‡§  
apriester@mednet.ucla.edu  
Shyam Natarajan‡§  
snatarajan@mednet.ucla.edu  
William Speier†  
wspeier@mednet.ucla.edu  
Steven S. Raman†  
sraman@mednet.ucla.edu  
Leonard S. Marks‡§  
lmarks@mednet.ucla.edu  
Corey W. Arnold‡¶  
cwarnold@mednet.ucla.edu

Abstract

Prostate biopsy is commonly used to detect and stage prostate cancer. However, accurate biopsy targeting requires the prior identification of appropriate targets for sampling. Imaging-based decision support systems have significant potential to improve targeting by predicting which potential biopsy locations are most likely to have cancer, and which can safely be left unsampled. In this study, we developed an algorithm to predict whether a given biopsy would find clinically significant prostate cancer using MRI data alone. Using a dataset of 11,095 biopsies collected from 711 patients, we developed a support vector machine for predicting the presence of clinically significant prostate cancer with a test set AUC of 0.72, precision of 0.877, and recall of 0.74.

1 Introduction

Prostate cancer is the most common newly diagnosed cancer and second most deadly cancer of American men (2). Transrectal ultrasound-guided (TRUS) MR fusion biopsy is a diagnostic procedure for prostate cancer in which potential targets for sampling are identified by radiologists on multiparametric MRI (mpMRI) of the prostate, and then ultrasound guidance is used to collect biopsies from those targets (6). This methodology has been demonstrated to be more sensitive than unguided biopsy. (3;1). However, interpretation of prostate mp-MRI is challenging and has substantial inter-reader variability, suggesting a need for computer-based tools (7). In this work, we aim to develop a model for predicting whether or not clinically significant prostate cancer is likely to be found in a given biopsy location based on mpMRI.

*Department of Biomedical Engineering, Xi’an Jiaotong University  
†Computational Integrated Diagnostics, Department of Radiological Sciences, University of California Los Angeles  
‡Department of Bioengineering, University of California Los Angeles  
§Department of Urology, University of California Los Angeles  
¶Corresponding Author

Figure 1: Our dataset consists of biopsy locations with associated Gleason scores and mpMRI studies with prostate and region of interest contours. A) Example prostate with illustrated biopsy locations. Biopsies were separated into two groups by Gleason score (GS > 3+3 and GS ≤ 3+3). mpMRI region of interest is also illustrated for comparison. B) Interpolation was used to create simulated MR planes perpendicular to the biopsy. C) The four MR data types from an example patient. The ROI referred to in A is highlighted in a red square; the yellow oval represents the prostate boundary.

2 Methods

2.1 Data acquisition

Data for a total of 759 patients was retrieved from clinical records retrospectively. All 759 patients underwent TRUS MR fusion biopsy using the Artemis guided biopsy system between 2010 and 2016. Before the biopsy procedure, each patient underwent multiparametric MR imaging, and a clinical radiologist identified regions of interest in the image to target for biopsy (ROIs). The patients then underwent TRUS biopsy, and 8-16 biopsy cores were retrieved from each patient’s prostate using the sampling device. During sampling, the spatial coordinates of each retrieved core were recorded. Each core was then evaluated by a pathologist and assigned a primary and secondary Gleason score. For this study, we considered a biopsy core to contain clinically significant prostate cancer the Gleason score was greater than 3+3. Four types of imaging studies were retrieved from our Picture Archive and Communication System (PACS): T2-weighted images, apparent diffusion coefficient (ADC) maps, Kep maps, and Ktrans maps.

2.2 Preprocessing and Biopsy Modeling

Cores were included in our analysis unless they met at least one of three exclusion criteria: 1) MRI study was missing or invalid, 2) assigned Gleason grades were missing or invalid, or 3) the biopsy core was entirely outside of the prostate contour. After exclusion, 675 patients with a total of 9,384 biopsy cores remained. Of these retained cores, 981 (10.5%) were labeled as clinically significant. Biopsy locations are represented by the Artemis system as a series of 20 points. For each point, we extracted a square region of MR data perpendicular to the biopsy at that point using 8-way linear interpolation between MR voxels. For any portions of the biopsy not contained within the prostate, mean padding was used to replace the excluded portion.

2.3 Feature Extraction and Selection

In order to represent heterogeneity along the length of a core, we initially split each core into two halves and computed features on each half; these features were then averaged together. We extracted a variety of features, including Haralick and wavelet textures (9,8), statistical features (such as mean, variance, and percentile values) (4), and the histogram of oriented gradients (HOG) (5).
2.4 Dimension Reduction and Learning

Recursive feature elimination (RFE) and principle component analysis (PCA) were applied to reduce the dimensionality of the feature space. All features were normalized to zero mean and a unit variance. A bagging and balanced-weight support vector machine (SVM) with a radial basis function kernel was trained to classify clinically significant biopsy. A total of 539 patients (79.9%) were randomly selected to use as the training set while the remaining patients were used as a held-out test set. All parameters were optimized under eight-fold cross-validation on the training set. ROC curves were obtained and the area under the ROC curve (AUC) was used as the evaluation metric.

3 Results

As shown in Fig. 2, the mean AUC of the eight-fold cross validation was approximately 0.71 ± 0.02 with precision of 0.86 ± 0.02 and sensitivity of 0.72 ± 0.01, respectively, showing acceptable performance with small variance. The AUC of the test set is 0.72 with a precision of 0.87 and sensitivity of 0.74, and the f1-score of testing set is 0.80.

4 Conclusion

In this study, we built a classifier that predicts the existence of clinically significant prostate cancer at proposed biopsy locations using MR imaging data alone with acceptable performance. Our results demonstrate the potential for use of MR-based decision support tools in optimizing biopsy targeting for prostate cancer diagnosis. Substantial opportunities for further improvements exist that we continue to pursue. This includes the use of additional types of MR data (such as a calculated high b-value map and raw perfusion data) and the use of other types of models (such a deep learning models) for both feature extraction and prediction.
Acknowledgments

Wen Shi acknowledges support from the UCLA Cross-disciplinary Scholars in Science and Technology program. Karthik Sarma acknowledges support from NIH NCI F30CA210329 and the UCLA-Caltech Medical Scientist Training Program. This work was performed on hardware provided in part by an NVIDIA Academic Hardware Grant. This work was supported in part by grants from the National Cancer Institute: R21CA220352, R01CA218547, R01CA195505, and R01CA158627. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

References


